

DAN BURTON, INDIANA
JOHN L. MICA, FLORIDA
TODD RUSSELL PLATTS, PENNSYLVANIA
MICHAEL R. TURNER, OHIO
PATRICK McHENRY, NORTH CAROLINA
JIM JORDAN, OHIO
JASON CHAFFETZ, UTAH
CONNIE MACK, FLORIDA
TIM WALBERG, MICHIGAN
JAMES LANKFORD, OKLAHOMA
JUSTIN AMASH, MICHIGAN
ANN MARIE BUERKLE, NEW YORK
PAUL A. GOSAR, D.D.S., ARIZONA
RAUL R. LABRADOR, IDAHO
PATRICK MEEHAN, PENNSYLVANIA
SCOTT DesJARLAIS, M.D., TENNESSEE
JOE WALSH, ILLINOIS
TREY GOWDY, SOUTH CAROLINA
DENNIS A. ROSS, FLORIDA
FRANK C. GUINTA, NEW HAMPSHIRE
BLAKE FARENTHOLD, TEXAS
MIKE KELLY, PENNSYLVANIA

Congress of the United States

House of Representatives

COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
FACSIMILE (202) 225-3974
MINORITY (202) 225-5051

<http://oversight.house.gov>

EDOLPHUS TOWNS, NEW YORK
CAROLYN B. MALONEY, NEW YORK
ELEANOR HOLMES NORTON,
DISTRICT OF COLUMBIA
DENNIS J. KUCINICH, OHIO
JOHN F. TIERNEY, MASSACHUSETTS
WM. LACY CLAY, MISSOURI
STEPHEN F. LYNCH, MASSACHUSETTS
JIM COOPER, TENNESSEE
GERALD E. CONNOLLY, VIRGINIA
MIKE QUIGLEY, ILLINOIS
DANNY K. DAVIS, ILLINOIS
BRUCE L. BRALEY, IOWA
PETER WELCH, VERMONT
JOHN A. YARMUTH, KENTUCKY
CHRISTOPHER S. MURPHY, CONNECTICUT
JACKIE SPEIER, CALIFORNIA

LAWRENCE J. BRADY
STAFF DIRECTOR

November 30, 2011

The Honorable Trey Gowdy
Chairman
Subcommittee on Health Care, District of Columbia,
Census and National Archives
U.S. House of Representatives
Washington, DC 20515

Dear Mr. Chairman:

Thank you very much for holding today's hearing on the causes and effects of critical drug shortages in the United States. We agree that this is a vital issue that deserves close and careful congressional scrutiny, and we commend you for initiating hearings on this topic.

Today, we heard valuable testimony from oncologists and other health and medical experts about the tragic effects of these shortages, including the withholding of potentially life-saving care for critically ill patients. For example, Dr. Michelle Hudspeth, the Division Director of Pediatric Hematology and Oncology at Medical University of South Carolina, testified:

What I'm afraid is that you're going to set a hierarchy of treatment. If you've got the money to pay, obtain some drug, travel to Canada, you can get treatment. But the folks who don't have the finances to do that are left behind. And who is that going to be? It's going to be the kids.


As we mentioned at today's hearing, the next logical step in this investigation is to hold a hearing with the drug manufacturers who are experiencing these shortages in order to obtain their opinions about the causes and effects of these shortages, as well as what reforms can be implemented to avoid shortages in the future.

For these reasons, we respectfully request that you schedule a hearing this month with the following manufacturers of drugs currently on the Food and Drug Administration's shortage list:


- Bedford Laboratories (maker of leucovorin)
- APP Pharmaceuticals (maker of fluorouracil)
- Hospira (maker of paclitaxel)
- Teva Pharmaceuticals (maker of fluorouracil)
- Sandoz Pharmaceuticals (maker of paclitaxel)

We were very encouraged by your positive comments at today's hearing indicating an openness to taking this step and a willingness to work in a bipartisan manner on this investigation. We look forward to working together, and we thank you for your consideration of this request.

Sincerely,



Elijah E. Cummings
Ranking Member
Committee on Oversight and
Government Reform



Danny K. Davis
Ranking Member
Subcommittee on Health Care, District of
Columbia, Census and National Archives

cc: The Honorable Darrell E. Issa, Chairman
Committee on Oversight and Government Reform